ATE208634T1 - Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc - Google Patents
Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-mycInfo
- Publication number
- ATE208634T1 ATE208634T1 AT94906558T AT94906558T ATE208634T1 AT E208634 T1 ATE208634 T1 AT E208634T1 AT 94906558 T AT94906558 T AT 94906558T AT 94906558 T AT94906558 T AT 94906558T AT E208634 T1 ATE208634 T1 AT E208634T1
- Authority
- AT
- Austria
- Prior art keywords
- cell proliferation
- smooth muscle
- muscle cell
- pct
- myc
- Prior art date
Links
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US479993A | 1993-01-07 | 1993-01-07 | |
| PCT/US1994/000265 WO1994015646A1 (en) | 1993-01-07 | 1994-01-07 | Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE208634T1 true ATE208634T1 (de) | 2001-11-15 |
Family
ID=21712588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94906558T ATE208634T1 (de) | 1993-01-07 | 1994-01-07 | Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6159946A (de) |
| EP (1) | EP0690726B1 (de) |
| JP (1) | JPH08505397A (de) |
| KR (1) | KR100316205B1 (de) |
| CN (1) | CN1119830A (de) |
| AT (1) | ATE208634T1 (de) |
| AU (1) | AU685080B2 (de) |
| BR (1) | BR9405707A (de) |
| CA (1) | CA2153158A1 (de) |
| CZ (1) | CZ172395A3 (de) |
| DE (1) | DE69429087T2 (de) |
| DK (1) | DK0690726T3 (de) |
| ES (1) | ES2167358T3 (de) |
| HU (1) | HU220969B1 (de) |
| PT (1) | PT690726E (de) |
| WO (1) | WO1994015646A1 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| ATE208634T1 (de) * | 1993-01-07 | 2001-11-15 | Univ Jefferson | Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc |
| US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
| AU8019694A (en) * | 1993-10-15 | 1995-05-04 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
| US6133242A (en) * | 1993-10-15 | 2000-10-17 | Thomas Jefferson Univerisity | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
| US5660855A (en) * | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
| WO1996024334A1 (en) * | 1995-02-10 | 1996-08-15 | Nexstar Pharmaceuticals, Inc. | Lipid constructs for cytoplasmic delivery of agents |
| US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| WO1997014440A1 (en) * | 1995-10-19 | 1997-04-24 | Johnson & Johnson Interventional Systems | Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia |
| US5681558A (en) * | 1995-11-30 | 1997-10-28 | Berlex Laboratories, Inc. | Method of using beta-interferons to treat restenosis |
| JP3981416B2 (ja) | 1997-04-10 | 2007-09-26 | ユニバーシティ メディカル センター ナイメーヘン | Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途 |
| JP2002525037A (ja) * | 1998-08-13 | 2002-08-13 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 再狭窄を治療するためのｄｎａザイムおよび方法 |
| JP2002535015A (ja) * | 1999-01-29 | 2002-10-22 | エイブイアイ バイオファーマ， インコーポレイテッド | 標的ｒｎａを検出するための非侵襲性方法 |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20000065690A (ko) * | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법 |
| PT1222266E (pt) | 1999-09-29 | 2006-07-31 | Diagnocure Inc | Arn mensageiro de pca3 em tecidos benignos e malignos da prostata |
| US6746686B2 (en) | 2000-01-24 | 2004-06-08 | Biocompatibles Uk Limited | Coated implants |
| AU2001255179A1 (en) * | 2000-03-24 | 2001-10-08 | Temple University-Of The Commonwealth System Of Higher Education | Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents |
| AU2002224787A1 (en) * | 2000-10-23 | 2002-05-06 | Mermaid Pharmaceuticals Gmbh | Method for temporally controlling antisense-mediated gene inactivation |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| JP2004537517A (ja) * | 2001-05-17 | 2004-12-16 | エイブイアイ バイオファーマ， インコーポレイテッド | ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ |
| US20050159378A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US7893248B2 (en) * | 2002-02-20 | 2011-02-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US7241581B2 (en) * | 2002-08-16 | 2007-07-10 | Rigel Pharmaceuticals, Inc. | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein |
| US7407672B2 (en) * | 2002-11-04 | 2008-08-05 | National Heart Center | Composition derived from biological materials and method of use and preparation |
| SI1569695T1 (sl) | 2002-11-13 | 2013-08-30 | Genzyme Corporation | Protismiselna modulacija ekspresije apolipoproteina B |
| EP2336318B1 (de) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense-modulation von apolipoprotein-b-expression |
| US7781415B2 (en) * | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| AU2004209578A1 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| CA2523672C (en) * | 2003-04-29 | 2012-07-17 | Avi Biopharma, Inc. | Compositions for enhancing transport of molecules into cells |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| KR100818047B1 (ko) | 2005-11-25 | 2008-03-31 | 한국원자력연구원 | 평활근-22α의 활성을 억제하여 암세포의 사멸을 촉진하는방법 및 평활근-22α의 활성 억제제를 유효성분으로포함하는 항암제 |
| EP3443976A1 (de) * | 2007-06-29 | 2019-02-20 | Sarepta Therapeutics, Inc. | Gewebespezifische peptidkonjugate und verfahren |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| RU2620970C2 (ru) * | 2008-12-04 | 2017-05-30 | КьюРНА,Инк., | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| DK2529015T3 (en) * | 2010-01-25 | 2018-02-26 | Curna Inc | TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1 |
| US9222088B2 (en) * | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9228189B2 (en) | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| EP3302489A4 (de) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten |
| SMT202200366T1 (it) | 2016-12-19 | 2022-11-18 | Sarepta Therapeutics Inc | Coniugati di oligomeri per salto di esone per distrofia muscolare |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| SE462364B (sv) * | 1988-09-30 | 1990-06-18 | Goeran Hansson | Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos |
| US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| ES2083593T3 (es) * | 1990-08-03 | 1996-04-16 | Sterling Winthrop Inc | Compuestos y metodos para inhibir la expresion de genes. |
| US5122048A (en) * | 1990-09-24 | 1992-06-16 | Exxon Chemical Patents Inc. | Charging apparatus for meltblown webs |
| CA2082411A1 (en) * | 1991-06-28 | 1992-12-29 | Robert D. Rosenberg | Localized oligonucleotide therapy |
| AU3129993A (en) * | 1991-11-08 | 1993-06-07 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| US5756476A (en) * | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
| US5821234A (en) * | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
| WO1994015943A1 (en) * | 1992-12-31 | 1994-07-21 | Texas Biotechnology Corporation | Antisense molecules directed against a platelet derived growth factor receptor related gene |
| WO1994015645A1 (en) * | 1992-12-31 | 1994-07-21 | Texas Biotechnology Corporation | Antisense molecules directed against genes of the raf oncogene family |
| ATE208634T1 (de) * | 1993-01-07 | 2001-11-15 | Univ Jefferson | Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc |
| EP0702518B1 (de) * | 1993-06-11 | 2003-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet |
| AU8019694A (en) * | 1993-10-15 | 1995-05-04 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
-
1994
- 1994-01-07 AT AT94906558T patent/ATE208634T1/de not_active IP Right Cessation
- 1994-01-07 HU HU9502061A patent/HU220969B1/hu not_active IP Right Cessation
- 1994-01-07 JP JP6516242A patent/JPH08505397A/ja not_active Ceased
- 1994-01-07 CA CA002153158A patent/CA2153158A1/en not_active Abandoned
- 1994-01-07 EP EP94906558A patent/EP0690726B1/de not_active Expired - Lifetime
- 1994-01-07 DE DE69429087T patent/DE69429087T2/de not_active Expired - Fee Related
- 1994-01-07 US US08/481,341 patent/US6159946A/en not_active Expired - Fee Related
- 1994-01-07 WO PCT/US1994/000265 patent/WO1994015646A1/en not_active Ceased
- 1994-01-07 CN CN94190891A patent/CN1119830A/zh active Pending
- 1994-01-07 PT PT94906558T patent/PT690726E/pt unknown
- 1994-01-07 BR BR9405707A patent/BR9405707A/pt not_active Application Discontinuation
- 1994-01-07 ES ES94906558T patent/ES2167358T3/es not_active Expired - Lifetime
- 1994-01-07 DK DK94906558T patent/DK0690726T3/da active
- 1994-01-07 KR KR1019950702808A patent/KR100316205B1/ko not_active Expired - Fee Related
- 1994-01-07 AU AU60235/94A patent/AU685080B2/en not_active Ceased
- 1994-01-07 CZ CZ951723A patent/CZ172395A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU685080B2 (en) | 1998-01-15 |
| KR100316205B1 (ko) | 2002-04-24 |
| JPH08505397A (ja) | 1996-06-11 |
| EP0690726A1 (de) | 1996-01-10 |
| EP0690726B1 (de) | 2001-11-14 |
| US6159946A (en) | 2000-12-12 |
| KR960700076A (ko) | 1996-01-19 |
| ES2167358T3 (es) | 2002-05-16 |
| CZ172395A3 (en) | 1996-03-13 |
| HUT71937A (en) | 1996-02-28 |
| EP0690726A4 (de) | 1998-10-07 |
| AU6023594A (en) | 1994-08-15 |
| BR9405707A (pt) | 1996-08-06 |
| DE69429087T2 (de) | 2002-07-11 |
| CN1119830A (zh) | 1996-04-03 |
| PT690726E (pt) | 2002-05-31 |
| HU220969B1 (hu) | 2002-07-29 |
| DK0690726T3 (da) | 2002-03-11 |
| HU9502061D0 (en) | 1995-09-28 |
| DE69429087D1 (de) | 2001-12-20 |
| CA2153158A1 (en) | 1994-07-21 |
| WO1994015646A1 (en) | 1994-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE208634T1 (de) | Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc | |
| EP0840608A4 (de) | Behandlung und vorbeugung von neoplasmen mit salzen von aminoimidazolcarboxamid und 5-amino-oder substituierten amino 1,2,3-triazolen | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| PL323825A1 (en) | Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin | |
| SI0882021T1 (en) | New phenanthridines | |
| DE69424537D1 (de) | Therapeutischer wirkstoff zur behandlung von melanomen | |
| EP0871496A4 (de) | ||
| GR3029405T3 (en) | COMBINATION OF A CHOLESTEROL BIOSYNTHESIS INHIBITOR AND A -g(b)-LACTAM CHOLESTEROL ABSORPTION INHIBITOR. | |
| GR20010300007T1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| ZA987491B (en) | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation | |
| GR20010300033T1 (en) | Raf kinase inhibitors | |
| ATE321452T1 (de) | Tetracycline verbindungen zur behandlung von spezifischen krebsarten | |
| ATE185548T1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
| CY2431B1 (en) | Novel phenanthridines substituted in the 6 position. | |
| DK0622985T3 (da) | Forbedringer i forbindelse med jordbehandling | |
| DE69232629D1 (de) | Verwendung von transglutaminasehemmer zur behandlung des narbegewebes | |
| DE59410358D1 (de) | Verwendung von carnosin in kombination mit urocaninsäure zur behandlung von photodermatosen | |
| DE69814444D1 (de) | Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation | |
| DE69319590D1 (de) | Melamine derivate zur verwendung in der behandlung von krebs | |
| GB9920502D0 (en) | Portable terminal | |
| ATE309352T1 (de) | Inhibitoren der nf-kb aktivierung | |
| DK0674521T3 (da) | Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on | |
| ATE208202T1 (de) | Verwendung von dimeticon zur behandlung der konstipation | |
| ATE200624T1 (de) | Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis | |
| DE69407780D1 (de) | Zusammensetzung zur behandlung von pflanzenmaterial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |